Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants

NewsGuard 100/100 Score

In a recent study posted to the medRxiv* preprint server, the researchers assessed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) booster vaccine on the SARS-CoV-2 Omicron variant. 

Study: High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination. Image Credit: Firn/Shutterstock
Study: High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination. Image Credit: Firn/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The waning efficacy of the coronavirus disease 2019 (COVID-19) vaccines has led to the administration of booster vaccines to protect against infection and disease severity. However, there is insufficient knowledge regarding the effectiveness of the booster vaccine against SARS-CoV-2 Omicron BA.2 lineage.

The study and results

The researchers estimated the booster vaccine effectiveness and neutralizing activity induced against the SARS-CoV-2 Omicron BA.2 lineage in the present study.

The team obtained blood samples from a total of 84 physicians practicing at the Kobe University Hospital, Japan. The eligible participants had received their second BNT162b2 dose seven months prior and their booster vaccine dose almost two weeks after the beginning of the study. None of the participants reported a history of COVID-19 infection. A serum neutralizing assay was performed against BA.2 using an authentic virus.    

The study results showed that the median age of the participating physicians was 44 years. Most of the participants had very low to no titer of neutralizing antibodies against the SARS-CoV-2 Omicron BA.2 lineage seven months after the primary vaccination with two BNR162b2 doses. However, the titer was observed to increase remarkably two weeks after receiving the booster vaccination.

Conclusion

The study findings showed that the COVID-19 booster vaccine sufficiently induced neutralizing antibodies against the SARS-CoV-2 BA.2 lineage. Furthermore, a booster dose of the BNT162b2 mRNA vaccine effectively elicited a significant cross-neutralizing response against other SARS-CoV-2 variants. 

Overall, this indicated that the booster vaccine could successfully curb the rampant transmission of BA.2 and activate memory B cells to stimulate further epitopes that identify neutralizing antibodies that are conserved in all SARS-CoV-2 variants.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2023, May 13). Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants. News-Medical. Retrieved on May 25, 2024 from https://www.news-medical.net/news/20220422/Booster-dose-of-BNT162b2-mRNA-vaccine-induces-a-high-cross-neutralizing-response-against-SARS-CoV-2-variants.aspx.

  • MLA

    Kunkalikar, Bhavana. "Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants". News-Medical. 25 May 2024. <https://www.news-medical.net/news/20220422/Booster-dose-of-BNT162b2-mRNA-vaccine-induces-a-high-cross-neutralizing-response-against-SARS-CoV-2-variants.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants". News-Medical. https://www.news-medical.net/news/20220422/Booster-dose-of-BNT162b2-mRNA-vaccine-induces-a-high-cross-neutralizing-response-against-SARS-CoV-2-variants.aspx. (accessed May 25, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2023. Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants. News-Medical, viewed 25 May 2024, https://www.news-medical.net/news/20220422/Booster-dose-of-BNT162b2-mRNA-vaccine-induces-a-high-cross-neutralizing-response-against-SARS-CoV-2-variants.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Curcuminoid compounds show promise against COVID-19 in neuronal cells